Keeping details private, but things going well.
Just a guess
Should help solidify the 1.80's base forming.
They just filed a shelf so they'll be raising money soon.
I'm guessing the maintain overweight was intended for the sheep and Bairds lowering the price target $11 bucks to below current price was intended for Baird clients. Somehow they got the release messed up.
Hmmm, some ticked off analysts this morning.
It's an inhaled insulin, there will be some % with pulminary sensitivities or latent lung issues that will have problems. So it won't be for everyone, but I think it will take a large share of the market.
MKND pretty much a slam dunk with label issues so high single digits likely. ARIA has more risk and more pop potential. What's your appetite for risk? There's your answer.
Wait, you wrote 3x earnings at $14, that assumes no expenses at all to earn that revenue. That's not too realistic. So, you have to estimate some kind of net margin on that $360MM revenue, no? Perhaps $60MM after tax times say a 10x multiple that's about $600MM or $8-9 as a target, discount that back a couple years you get roughly $6 bucks. So looks fairly valued to me.
Two things. First are you using earnings and sales interchangeably? Did you want to clarify that? Also, peak sales is used for target price not current price, you have to discount back to get current value.
I don't see anything to get excited about for the next 6 months at least. We all know we're starting the trials. Not sure what else there is to look forward to at this point.